Development of Clinical Assessment Technique Using Multi-radiotracer PET/MR in Prostate Cancer
NCT ID: NCT01938339
Last Updated: 2013-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
60 participants
INTERVENTIONAL
2012-05-31
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* to establish the optimal imaging technique of PET/MR using multiple radioactive tracers for prostate cancer
* to establish the imaging biomarker using PET/MR for clinical assessment of prostate cancer and early detection of recurrent prostate cancer
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Recruiting 30 patients with prostate cancer ahead to radical prostatectomy
* PET/MR using 18F-choline with dedicated prostate MRI in all patients
* PET/MR using 18fluoride(F)-fluorodeoxyglucose(FDG)in all patients after 2-7 days
* PET/CT using 18F-FDG in all patient immediate after 18F-FDG PET/MR
* outcome assessment: comparison of scan time, image quality, tumor detection rate, standardized uptake values of lesions
* establishing optimal imaging technique for prostate PET/MR
To establish the imaging biomarker using PET/MR for clinical assessment of prostate cancer
* comparison of findings on PET/MR, MRI and PET/CT with pathological mapping after radical prostatectomy
* outcome assessment: accuracy of PET/MR for localization and staging of prostate cancer compared with MRI only and PET/CT only
To establish the imaging biomarker using PET/MR for early detection of recurrent prostate cancer
* Recruiting 15 patients with recurrent prostate cancer treated by surgery, hormone, or radiation therapy
* Recruiting 15 patients with treated prostate cancer without recurrence
* PET/MR using 18F-choline with dedicated prostate MRI in all patients
* PET/MR using 18F-FDG in all patients after 2-7 days
* PET/CT using 18F-FDG in all patient immediate after 18F-FDG PET/MR
* comparison of findings on PET/MR, MRI, and PET/CT with clinical data in two patient groups with or without recurrent prostate cancer
* outcome assessment: accuracy of PET/MR for early detection and localization of recurrent prostate cancer compared with MRI only and PET/CT only
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PET/MR
Multi-radiotracer PET/MR will be performed to compare the accuracy of tumor detection in patient with primary prostate cancer
PET/MR
Multi-radiotracer PET/MR will be performed in patients with primary and recurrent prostate cancer
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PET/MR
Multi-radiotracer PET/MR will be performed in patients with primary and recurrent prostate cancer
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patient with prostate cancer treated
* patient with prostate cancer recurrent
Exclusion Criteria
* Patient with severe renal impairment
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jeong Yeon Cho, MD
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Hyeon Jin Kim, RN
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PETMR-Prostate
Identifier Type: -
Identifier Source: org_study_id